NO771860L - P}visning av kreft. - Google Patents

P}visning av kreft.

Info

Publication number: NO771860L
Authority: NO; Norway
Prior art keywords: cancer; tumor; malignant melanoma; extract; patients
Prior art date: 1976-05-27

Application number

NO771860A

Other languages

English (en)

Norwegian (no)

Inventor

Jose Ramon Marti

David Marshall Parks Thompson

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-05-27

Filing date

1977-05-26

Publication date

1977-11-29

1977-05-26 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1977-11-29 Publication of NO771860L publication Critical patent/NO771860L/no

Links

206010028980 Neoplasm Diseases 0.000 title claims description 65
201000011510 cancer Diseases 0.000 title claims description 22
201000001441 melanoma Diseases 0.000 claims description 56
239000000284 extract Substances 0.000 claims description 51
210000000265 leukocyte Anatomy 0.000 claims description 49
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 41
238000000034 method Methods 0.000 claims description 19
206010005003 Bladder cancer Diseases 0.000 claims description 14
210000004369 blood Anatomy 0.000 claims description 8
239000008280 blood Substances 0.000 claims description 8
206010033128 Ovarian cancer Diseases 0.000 claims description 5
206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
201000005202 lung cancer Diseases 0.000 claims description 4
208000020816 lung neoplasm Diseases 0.000 claims description 4
201000001531 bladder carcinoma Diseases 0.000 claims description 3
208000010570 urinary bladder carcinoma Diseases 0.000 claims description 3
206010008342 Cervix carcinoma Diseases 0.000 claims 1
208000011767 Sarcoma of cervix uteri Diseases 0.000 claims 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
239000006286 aqueous extract Substances 0.000 claims 1
201000010881 cervical cancer Diseases 0.000 claims 1
201000007270 liver cancer Diseases 0.000 claims 1
208000014018 liver neoplasm Diseases 0.000 claims 1
239000000427 antigen Substances 0.000 description 26
102000036639 antigens Human genes 0.000 description 26
108091007433 antigens Proteins 0.000 description 26
210000004027 cell Anatomy 0.000 description 15
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 12
238000012360 testing method Methods 0.000 description 12
201000005112 urinary bladder cancer Diseases 0.000 description 12
239000002609 medium Substances 0.000 description 11
206010006187 Breast cancer Diseases 0.000 description 10
239000012895 dilution Substances 0.000 description 10
238000010790 dilution Methods 0.000 description 10
239000011521 glass Substances 0.000 description 10
208000026310 Breast neoplasm Diseases 0.000 description 9
238000011534 incubation Methods 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
230000003211 malignant effect Effects 0.000 description 8
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000024932 T cell mediated immunity Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
210000005259 peripheral blood Anatomy 0.000 description 5
239000011886 peripheral blood Substances 0.000 description 5
210000003932 urinary bladder Anatomy 0.000 description 5
230000001464 adherent effect Effects 0.000 description 4
230000008260 defense mechanism Effects 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
241000699670 Mus sp. Species 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
210000003567 ascitic fluid Anatomy 0.000 description 2
238000009534 blood test Methods 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
230000002906 microbiologic effect Effects 0.000 description 2
210000003800 pharynx Anatomy 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
238000002271 resection Methods 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
206010061728 Bone lesion Diseases 0.000 description 1
208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000032972 Conjunctival malignant melanoma Diseases 0.000 description 1
206010073069 Hepatic cancer Diseases 0.000 description 1
206010019909 Hernia Diseases 0.000 description 1
208000007433 Lymphatic Metastasis Diseases 0.000 description 1
206010025652 Malignant melanoma in situ Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
241001674788 Pasites Species 0.000 description 1
206010043515 Throat cancer Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
201000008274 breast adenocarcinoma Diseases 0.000 description 1
208000011803 breast fibrocystic disease Diseases 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
201000001883 cholelithiasis Diseases 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000002250 liver carcinoma Diseases 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000005297 pyrex Substances 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000011870 unpaired t-test Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Oncology (AREA)
Food Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO771860A 1976-05-27 1977-05-26 P}visning av kreft. NO771860L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US69045476A	1976-05-27	1976-05-27

Publications (1)

Publication Number	Publication Date
NO771860L true NO771860L (no)	1977-11-29

Family

ID=24772522

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO771860A NO771860L (no)	1976-05-27	1977-05-26	P}visning av kreft.

Country Status (18)

Country	Link
JP (1)	JPS52145517A (sv)
AT (1)	AT357690B (sv)
AU (1)	AU506539B2 (sv)
BE (1)	BE855063A (sv)
DE (1)	DE2724114A1 (sv)
DK (1)	DK233277A (sv)
ES (1)	ES459164A1 (sv)
FI (1)	FI771646A (sv)
FR (1)	FR2352533A1 (sv)
GB (1)	GB1520208A (sv)
IE (1)	IE45284B1 (sv)
IL (1)	IL52133A0 (sv)
LU (1)	LU77413A1 (sv)
NL (1)	NL7705873A (sv)
NO (1)	NO771860L (sv)
NZ (1)	NZ184159A (sv)
SE (1)	SE7706203L (sv)
ZA (1)	ZA773026B (sv)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3999944A (en) *	1975-02-28	1976-12-28	Hoffmann-La Roche Inc.	Detection of breast cancer
US4043757A (en) *	1975-05-20	1977-08-23	Ortho Pharmaceutical Corporation	Method for detection of human mammary carcinoma

1977
- 1977-05-20 NZ NZ184159A patent/NZ184159A/xx unknown
- 1977-05-20 ZA ZA00773026A patent/ZA773026B/xx unknown
- 1977-05-20 IL IL52133A patent/IL52133A0/xx unknown
- 1977-05-20 AU AU25341/77A patent/AU506539B2/en not_active Expired
- 1977-05-24 FI FI771646A patent/FI771646A/fi not_active Application Discontinuation
- 1977-05-24 IE IE1055/77A patent/IE45284B1/en unknown
- 1977-05-25 JP JP6000577A patent/JPS52145517A/ja active Pending
- 1977-05-25 LU LU77413A patent/LU77413A1/xx unknown
- 1977-05-25 FR FR7715965A patent/FR2352533A1/fr active Granted
- 1977-05-26 ES ES459164A patent/ES459164A1/es not_active Expired
- 1977-05-26 DK DK233277A patent/DK233277A/da not_active Application Discontinuation
- 1977-05-26 GB GB22283/77A patent/GB1520208A/en not_active Expired
- 1977-05-26 SE SE7706203A patent/SE7706203L/sv not_active Application Discontinuation
- 1977-05-26 AT AT376977A patent/AT357690B/de not_active IP Right Cessation
- 1977-05-26 NO NO771860A patent/NO771860L/no unknown
- 1977-05-26 BE BE177925A patent/BE855063A/xx unknown
- 1977-05-27 DE DE19772724114 patent/DE2724114A1/de not_active Withdrawn
- 1977-05-27 NL NL7705873A patent/NL7705873A/xx not_active Application Discontinuation

Also Published As

Publication number	Publication date
NZ184159A (en)	1979-03-28
DE2724114A1 (de)	1977-12-15
ES459164A1 (es)	1978-04-16
JPS52145517A (en)	1977-12-03
AU2534177A (en)	1978-11-23
IE45284L (en)	1977-11-27
FR2352533A1 (fr)	1977-12-23
BE855063A (fr)	1977-11-28
IE45284B1 (en)	1982-07-28
AU506539B2 (en)	1980-01-10
IL52133A0 (en)	1977-07-31
ZA773026B (en)	1978-04-26
FI771646A (sv)	1977-11-28
NL7705873A (nl)	1977-11-29
GB1520208A (en)	1978-08-02
FR2352533B1 (sv)	1980-06-13
DK233277A (da)	1977-11-28
SE7706203L (sv)	1977-11-28
AT357690B (de)	1980-07-25
ATA376977A (de)	1979-12-15
LU77413A1 (sv)	1978-06-26

Publication	Publication Date	Title
McCoy et al.	1975	Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanoma
US3999944A (en)	1976-12-28	Detection of breast cancer
Zone et al.	1980	Circulating immune complexes of IgA type in dermatitis herpetiformis
Hollinshead et al.	1972	Reactivity between herpesvirus type 2-related soluble cervical tumor cell membrane antigens and matched cancer and control sera
SHELLEY et al.	1960	An unusual autoimmune syndrome: Erythema annulare centrifugum, generalized pigmentation and breast hypertrophy
Guinan et al.	1974	Urinary carcinoembryonic-like antigen levels in patients with bladder carcinoma
Friedman et al.	1957	A hemagglutination test for detection of adenovirus antibodies
Poskitt et al.	1974	RENAL DEPOSITION OF SOLUBLE IMMUNE COMPLEXES IN MICE BEARING B-16 MELANOMA: Characterization of Complexes and Relationship to Tumor Progress
Chen et al.	1966	An evaluation of Pasteurella pestis fraction-1-specific antibody for the confirmation of plague infections
Badger et al.	1978	Immunosuppressive activity and tissue polypeptide antigen content of human ascitic fluids
Pondman et al.	1960	The specificity of the complement antiglobulin test
Braathen et al.	1979	Evidence for Fc IgG receptors and complement factor C3b receptors in human choroid plexus
Preer Jr	1959	Studies on the Immobilization Antigens of Paramecium: I. Assay Methods
Sheikh et al.	1977	Malignant glial neoplasms: definition of a humoral host response to tumor-associated antigen (s)
Goodwin et al.	1972	Immune responses induced by human malignant melanoma in the rabbit
ABLIN	1976	Serum Antibody in Patients with Prostatic Cancer1
US3992516A (en)	1976-11-16	Direct fluorescent antibody composition and method for P. Pneumocystis carinii
Schultz et al.	1981	Glomerular disease in two patients with urticaria-cutaneous vasculitis and hypocomplementemia
NO771860L (no)	1977-11-29	P}visning av kreft.
Inami et al.	1973	Micro-hemagglutination tests for detection of native and single-strand DNA antibodies and circulating DNA antigen
Ilfeld et al.	1985	IgG monoclonal gammopathy in four patients with polymyalgia rheumatica.
Nelson	1974	Antigens of carcinoma of the cervix uteri. A study by means of immunofluorescence.
Svec	1969	Immunologic and clinical observations of granulocyte‐specific antinuclear antibodies
Baer et al.	1963	The immunology and chemistry of tuberculin: I. The isolation of dialyzable and nondialyzable tuberculin-active components from unheated BCG culture filtrates
Pesce et al.	1980	Immune complexes in transitional cell carcinoma